Mirvie, South San Francisco, Calif.-based leader inPredicting unexpected pregnancy complications, raised $90m to date after its close. Series B funding.
TheThe financing was managed by Decheng CapitalAdditional funding can be obtained from BlackRock managed funds and accounts. Foresite Capital, General Catalyst, GV, Khosla Ventures, MayfieldA debt facility is also available. Comerica Bank. Seven-time OlympicGold-medalist and maternal healthcare advocate Allyson FelixAlso, he joined the financing as an investor new to the project.
The funding will support the company’s continued clinical and commercial development of the proprietary MirvieThe RNA platform predicts preeclampsia or preterm birth months ahead of their actuality by revealing the underlying biology for each pregnancy.
LedBy Maneesh Jain, Co-FounderCEO MirvieIt provides an RNA platform which can reveal the biological causes of unexpected complications that were not previously hypothesized. ItIt allows patients to tailor existing interventions to their biology, and allows them to develop new interventions that directly target their causes. MirvieContinuing clinical research is being conducted to validate peer-reviewed evidence, improve the RNA platform performance, as well as to better understand other pregnancy complications.
MirvieIt is shaping the future for pregnancy health by providing expectant parents and doctors with an early detection window to intervene before unanticipated pregnancy complications become a crisis. One inFive pregnancies are affected by complications that have lifelong health consequences. The proprietary Mirvie RNA platform uses a simple blood test to reveal vital information about a pregnancy’s unique biology and detect complications months before they occur. TheIdea for MirvieThe founders’ personal experience with a prematurely born daughter was the catalyst for the creation of the company. Mirvie’s team of world-class scientists and entrepreneurs have brought to market category-first, non-invasive tests in both women’s health and inMillions of people today use early cancer detection.